unknown
Stage
1
Investors
About
BetaGlue Therapeutics develops YntraDose, an interventional radiotherapeutic platform that delivers Yttrium-90 microspheres directly into solid tumours to provide localized radiation treatment. The company is clinical-stage and targeting indications including pancreatic and liver cancers.
Explore BetaGlue Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.